About the Authors

Eiichi Tanaka

Roles Conceptualization, Investigation, Project administration, Resources, Writing – original draft

e-tanaka@twmu.ac.jp

Affiliation Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku, Tokyo, Japan

Eisuke Inoue

Roles Formal analysis, Methodology, Writing – review & editing

Affiliations Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku, Tokyo, Japan, Showa University Research Administration Center (SURAC), Showa University, Shinagawa, Tokyo, Japan

Ryoko Sakai

Roles Investigation, Methodology, Writing – review & editing

Affiliations Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku, Tokyo, Japan, Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Kiyose-city, Tokyo, Japan

Katsuhiko Iwasaki

Roles Data curation, Formal analysis, Methodology, Software, Writing – review & editing

Affiliations Division of Science and Analytics, Medilead Inc., Shinjuku, Tokyo, Japan, Healthcare Consulting, Inc., Chiyoda, Tokyo, Japan

Ayako Shoji

Roles Data curation, Formal analysis, Methodology, Software, Writing – original draft

Affiliations Division of Science and Analytics, Medilead Inc., Shinjuku, Tokyo, Japan, Healthcare Consulting, Inc., Chiyoda, Tokyo, Japan, Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo, Tokyo, Japan

Masayoshi Harigai

Roles Funding acquisition, Supervision, Writing – review & editing

Affiliation Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku, Tokyo, Japan

Competing Interests

ET has received lecture fees or consulting fees from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, Inc., Pfizer Japan Inc, Nichi-Iko Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Co., UCB Japan Co. Ltd. and Viatris Inc. ET has received research funding from Pfizer Inc. and UCB Japan Co. Ltd. EI received lecture fees from Eisai Co., Ltd. and Chugai Pharmaceutical Co., Ltd. RS has nothing to declare. KI was an employee of Medilead, Inc., which was commissioned to perform this study analysis by Tokyo Women's Medical University. During the study, KI was affiliated with Medilead, Inc., but is currently employed by Healthcare Consulting Inc. AS was an employee of Medilead, Inc., which was commissioned to perform this study analysis by Tokyo Women's Medical University. During the study, KI was affiliated with Medilead, Inc., but is currently employed by Healthcare Consulting Inc and the University of Tokyo. MH has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Eisai Co., Ltd., Eli Lilly Japan K.K., Kaken Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., UCB Japan Co., Ltd., and Viatris Japan. MH has received speaker’s fee from AbbVie Japan GK, Asahi Kasei Corp., Astra Zeneca K. K., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. MH is a consultant for AbbVie, Boehringer-ingelheim, Bristol Myers Squibb Co., and Teijin Pharma.